Holen Sie sich die Stockscreener-App
129.18
0.15%
0.19
Vorhandelsmarkt:
129.67
0.49
+0.38%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$128.99
Offen:
$130.57
24-Stunden-Volumen:
12.09M
Relative Volume:
1.96
Marktkapitalisierung:
$160.39B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
17.58
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
-5.17%
1M Leistung:
-2.65%
6M Leistung:
+5.52%
1J Leistung:
+18.49%
1-Tages-Spanne:
$128.01
$131.04
1-Wochen-Bereich:
$127.07
$137.20
52-Wochen-Spanne:
$104.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
129.18 | 160.15B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,125.27 | 961.99B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
228.17 | 537.39B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
224.94 | 383.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.26 | 283.29B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
148.40 | 274.12B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead applauds efforts to launch lenacapavir for HIV prevention in South Africa - The Pharma Letter
Daiwa Securities Group Inc. Has $40.43 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Cibc World Market Inc. Buys 97,779 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Arrowpoint Investment Partners Singapore Pte. Ltd. Invests $2.38 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Key facts: Gilead completes $7.8B Arcellx buy; closes Ouro Medicines deal - TradingView
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa - The Daily Tribune News
Gilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSN
US FDA approves Gilead's drug for deadly liver infection - MSN
Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - Stocktwits
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline - TradingView
Gilead Sciences (GILD) Has an HIV-and-Oncology Bridge That Makes the Base Business Harder to Ignore - AlphaStreet
Gilead and Lakefront complete Ouro Medicines acquisition - Investing.com
Gilead’s Livdelzi approved by NICE for PBC - The Pharma Letter
TD Asset Management Inc Sells 67,251 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead eyes PBC expansion for Livdelzi on positive one-year data - Clinical Trials Arena
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
GILD Reports Positive Results From Late-Stage Liver Disease Study - Yahoo Finance
With Cencora pact, Gilead looks to grow CAR-T treatment center network - Fierce Pharma
IDEAL Data Expands Gilead’s Livdelzi Evidence Into Lower-ALP PBC Population - Citeline News & Insights
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Weakness - Yahoo Finance
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance Singapore
Gilead Data On Livdelzi And Trodelvy Points To Broader Future Mix - simplywall.st
Marble Wealth LLC Acquires Shares of 9,588 Gilead Sciences, Inc. $GILD - MarketBeat
Natixis Advisors LLC Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
CIBC Asset Management Inc Buys 128,992 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. Acquires Significant Stake in Assembly Biosciences Inc. - GuruFocus
Gilead Sciences, Inc. Acquires Significant Stake in Assembly Bio - GuruFocus
Insider Sell: Daniel O'Day Sells 15,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
How Investors Are Reacting To Gilead Sciences (GILD) Expanding Liver And Oncology Drug Footprint - Yahoo! Finance Canada
Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O'day Sells 15,000 Shares - MarketBeat
Gilead (GILD) CEO Daniel O'Day sells 15,000 shares in pre-set 10b5-1 trades - Stock Titan
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome - Benzinga
Positive Phase III trial results for Gilead’s Livdelzi - The Pharma Letter
Gilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population - Fierce Pharma
Gilead Sciences (GILD) Announces New Results From a Post Hoc Analysis - Insider Monkey
Gilead Sciences, Inc. (GILD) Gains Attention as Livdelzi Demonstrates Long-Term Efficacy and Safety - Yahoo Finance
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC) - BioSpace
GILD Sees Positive Phase 3 Results for Livdelzi in Treating Prim - GuruFocus
Gilead reports positive Phase 3 trial results for PBC drug - Investing.com
Thompson Siegel & Walmsley LLC Boosts Position in Gilead Sciences, Inc. $GILD - MarketBeat
How Is Gilead Sciences's Stock Performance Compared to Other Healthcare Stocks - Yahoo Finance
Royal Bank Of Canada Upgrades Gilead Sciences (NASDAQ:GILD) to Moderate Buy - MarketBeat
BNP Paribas Has $11.36 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Inc. stock underperforms Monday when compared to competitors - MarketWatch
RBC Capital maintains Gilead Sciences stock rating on HIV franchise outlook - Investing.com UK
How Liver and Oncology Wins Will Impact Gilead Sciences (GILD) Investors - simplywall.st
RBC Capital maintains Gilead Sciences stock rating on HIV franchise outlook By Investing.com - Investing.com India
Gilead (GILD) to Showcase New Cancer Therapy Data - Insider Monkey
MUFG Securities EMEA plc Sells 58,888 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (GILD) Stock Analysis: Strong Buy Ratings And 17% Upside Potential - DirectorsTalk Interviews
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):